WO2003011309A3 - Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie - Google Patents
Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie Download PDFInfo
- Publication number
- WO2003011309A3 WO2003011309A3 PCT/EP2002/008154 EP0208154W WO03011309A3 WO 2003011309 A3 WO2003011309 A3 WO 2003011309A3 EP 0208154 W EP0208154 W EP 0208154W WO 03011309 A3 WO03011309 A3 WO 03011309A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- hypercholesterolaemia
- treating
- treating hypercholesterolaemia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02767244A EP1408992A2 (de) | 2001-07-20 | 2002-07-22 | Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie |
AU2002331279A AU2002331279A1 (en) | 2001-07-20 | 2002-07-22 | Pharmaceutical composition for treating hypercholesterolaemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10135493A DE10135493A1 (de) | 2001-07-20 | 2001-07-20 | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
DE10135493.2 | 2001-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011309A2 WO2003011309A2 (de) | 2003-02-13 |
WO2003011309A3 true WO2003011309A3 (de) | 2003-07-24 |
Family
ID=7692564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008154 WO2003011309A2 (de) | 2001-07-20 | 2002-07-22 | Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1408992A2 (de) |
AU (1) | AU2002331279A1 (de) |
DE (1) | DE10135493A1 (de) |
WO (1) | WO2003011309A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10233229A1 (de) * | 2002-07-22 | 2004-02-12 | S.K. Enterprise Gmbh | Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels |
DE10331202A1 (de) * | 2003-07-10 | 2005-03-31 | S.K. Enterprise Gmbh | Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms |
DE102006036285A1 (de) | 2006-08-03 | 2008-02-07 | "S.U.K." Beteiligungs Gmbh | Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms |
CN111587110A (zh) | 2018-01-12 | 2020-08-25 | 麦提麦迪制药有限公司 | 治疗慢性炎症性疾病的方法 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1808173A1 (de) * | 1967-11-15 | 1970-11-12 | Nieper Dr Med Hans A | Calciumorotat |
JPS63198630A (ja) * | 1987-02-13 | 1988-08-17 | Kao Corp | 脂質代謝改善剤 |
JPH04148651A (ja) * | 1990-10-12 | 1992-05-21 | Norihiro Kamata | 鉄分とカルシウムを強化したこんにゃく |
US5126150A (en) * | 1990-10-01 | 1992-06-30 | The Procter & Gamble Company | Compositions containing psyllium |
JPH05304928A (ja) * | 1992-04-29 | 1993-11-19 | Aroma Kagaku Kikai Kogyo:Kk | カルシウム添加食品の製造方法 |
CN1167581A (zh) * | 1997-07-09 | 1997-12-17 | 张永新 | 钙奶营养麦片 |
JPH1014534A (ja) * | 1996-06-27 | 1998-01-20 | Snow Brand Milk Prod Co Ltd | 栄養組成物 |
CN1245021A (zh) * | 1999-07-29 | 2000-02-23 | 王操 | A、d钙奶茶 |
CN1259384A (zh) * | 1999-01-06 | 2000-07-12 | 哈尔滨红太阳实业有限公司 | 牦牛骨髓壮骨粉及其加工方法 |
WO2000042024A1 (en) * | 1999-01-09 | 2000-07-20 | Astrazeneca Ab | Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt |
CN1282536A (zh) * | 2000-08-29 | 2001-02-07 | 刘国柱 | 胡萝卜银杏营养复合饮料配方及制作工艺 |
WO2001028999A1 (en) * | 1999-10-18 | 2001-04-26 | EGIS Gyógyszergyár Rt. | Process for the preparation of amorphous atorvastatin calcium |
US6403129B1 (en) * | 1999-12-27 | 2002-06-11 | Mac Farms, Inc. | Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet |
-
2001
- 2001-07-20 DE DE10135493A patent/DE10135493A1/de not_active Withdrawn
-
2002
- 2002-07-22 WO PCT/EP2002/008154 patent/WO2003011309A2/de not_active Application Discontinuation
- 2002-07-22 EP EP02767244A patent/EP1408992A2/de not_active Withdrawn
- 2002-07-22 AU AU2002331279A patent/AU2002331279A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1808173A1 (de) * | 1967-11-15 | 1970-11-12 | Nieper Dr Med Hans A | Calciumorotat |
JPS63198630A (ja) * | 1987-02-13 | 1988-08-17 | Kao Corp | 脂質代謝改善剤 |
US5126150A (en) * | 1990-10-01 | 1992-06-30 | The Procter & Gamble Company | Compositions containing psyllium |
JPH04148651A (ja) * | 1990-10-12 | 1992-05-21 | Norihiro Kamata | 鉄分とカルシウムを強化したこんにゃく |
JPH05304928A (ja) * | 1992-04-29 | 1993-11-19 | Aroma Kagaku Kikai Kogyo:Kk | カルシウム添加食品の製造方法 |
JPH1014534A (ja) * | 1996-06-27 | 1998-01-20 | Snow Brand Milk Prod Co Ltd | 栄養組成物 |
CN1167581A (zh) * | 1997-07-09 | 1997-12-17 | 张永新 | 钙奶营养麦片 |
CN1259384A (zh) * | 1999-01-06 | 2000-07-12 | 哈尔滨红太阳实业有限公司 | 牦牛骨髓壮骨粉及其加工方法 |
WO2000042024A1 (en) * | 1999-01-09 | 2000-07-20 | Astrazeneca Ab | Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt |
CN1245021A (zh) * | 1999-07-29 | 2000-02-23 | 王操 | A、d钙奶茶 |
WO2001028999A1 (en) * | 1999-10-18 | 2001-04-26 | EGIS Gyógyszergyár Rt. | Process for the preparation of amorphous atorvastatin calcium |
US6403129B1 (en) * | 1999-12-27 | 2002-06-11 | Mac Farms, Inc. | Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet |
CN1282536A (zh) * | 2000-08-29 | 2001-02-07 | 刘国柱 | 胡萝卜银杏营养复合饮料配方及制作工艺 |
Non-Patent Citations (13)
Title |
---|
ARCHIVES OF INTERNAL MEDICINE, vol. 152, no. 12, 1992, pages 2441 - 2444, ISSN: 0003-9926 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, BELL LARRY ET AL: "Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia.", XP002237123, Database accession no. PREV199395065748 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, DENKE MARGO A ET AL: "Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men.", XP002237122, Database accession no. PREV199396043148 * |
DATABASE WPI Section Ch Week 199351, Derwent World Patents Index; Class B04, AN 1993-408295, XP002237129 * |
DATABASE WPI Section Ch Week 199813, Derwent World Patents Index; Class D13, AN 1998-138203, XP002237128 * |
DATABASE WPI Section Ch Week 200042, Derwent World Patents Index; Class B05, AN 2000-476630, XP002237125 * |
DATABASE WPI Section Ch Week 200054, Derwent World Patents Index; Class B04, AN 2000-572814, XP002237127 * |
DATABASE WPI Section Ch Week 200132, Derwent World Patents Index; Class B04, AN 2001-300860, XP002237124 * |
DATABASE WPI Section Ch Week 200168, Derwent World Patents Index; Class B04, AN 2001-597454, XP002237126 * |
JOURNAL OF NUTRITION, vol. 123, no. 6, 1993, pages 1047 - 1053, ISSN: 0022-3166 * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 482 (C - 553) 15 December 1988 (1988-12-15) * |
PATENT ABSTRACTS OF JAPAN vol. 016, no. 431 (C - 0983) 9 September 1992 (1992-09-09) * |
TOUSSAINT ET AL: "Effect of Water Containing Calcium and Magnesium Sulfates on the Elimination of Cholesterol in the Rat", ARCHIVES INTERNATIONALES DE PHYSIOLOGIE ET DE BIOCHIMIE, VAILLANT CARMANNE, LIEGE, BE, vol. 96, no. 2, June 1988 (1988-06-01), pages 89 - 100, XP002100566, ISSN: 0003-9799 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002331279A1 (en) | 2003-02-17 |
WO2003011309A2 (de) | 2003-02-13 |
EP1408992A2 (de) | 2004-04-21 |
DE10135493A1 (de) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
HUP0401192A3 (en) | Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
PL1663185T3 (pl) | Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego | |
HK1090843A1 (en) | Pharmaceutical compositions for healing wounds | |
AU2002243023A1 (en) | Compositions for preventing and/or treating oral diseases | |
WO2002000227A3 (en) | Use of lanthanum compounds for the treatment of bone diseases | |
WO2003037368A3 (en) | Smad7 inhibitors for the treatment of cns diseases | |
YU82602A (sh) | Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze | |
AU2002248319A1 (en) | Pharmaceutical composition for the prevention and treatment of scar tissue | |
WO2005110413A3 (en) | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions | |
WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
AU2002322481A1 (en) | Use of r-nsaid compounds for anti-hiv treatment | |
SE0101082D0 (sv) | Novel use | |
BR0008603A (pt) | Método para tratamento de copd | |
EA200400436A1 (ru) | Медикаменты для профилактики и лечения бромидроза | |
AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
WO2003011309A3 (de) | Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie | |
WO2003024996A3 (de) | Antibakterielle makrozyklen | |
WO2002055096A3 (de) | Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen | |
WO2003000269A3 (de) | Neue verwendung für pde 10a-inhibitoren | |
WO2004055001A3 (en) | Rabeprazole calcium | |
WO2003013577A3 (en) | Use of il-18 inhibitors in hypersensitivity disorders | |
AU2002251202A1 (en) | Intimins for the prevention or treatment of infections: i | |
IL159511A0 (en) | Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VN ZA ZM ZW GH GM KE LS MW MZ SD SZ TZ UG ZM ZW AM Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002767244 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002767244 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |